Modern therapy of radioactive iodine-refractory differentiated thyroid cancer: resolution of the Expert Council

The meeting of experts, concerning the treatment of thyroid cancer was held in Moscow in June 2016. The aim of the meeting was unsolved tasks in the field of therapy of the patients with radioactive iodine-refractory differentiated thyroid cancer. Nowadays, this group of patients still has a poor prognosis with respect to life expectancy. The experts are faced with some difficulties in choosing the treatment tactics in patients after radioiodine therapy have become ineffective and we observe disease progression. And still valid questions remain unsolved: when should doctors stop therapy using radioactive iodine? When should patient start therapy using targeted agents? What kind of targeted agent should specialist choose for treatment of this desiase? How should one manage the developing side effects against the backdrop of targeted therapy? These and some other problems have been discussed within the framework of this counsel.